Given TIMD4's characteristic up‐regulation as a prognostic risk factor in renal carcinoma, systematic protein–drug molecular docking studies were conducted alongside functional validation through in vivo and in vitro experiments to explore TIMD4's druggable targets and verify its cancer‐promoting mechanisms. Here, TIMD4 is linked to cancer.